Stablecoin Development Corp
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608
Mailing Address
2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608
Phone
(510) 899-8800
Fiscal Year End
1231
EIN
680454536
Financial Overview
FY2025
$7.96M
Cash & Equivalents
$-3.80
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 11, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 10, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 29, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- NovaBay is undergoing a major strategic shift, selling all traditional pharmaceutical assets to pivot entirely into blockchain networks and digital assets.
- The company aims for potentially higher growth markets with its new digital asset focus, including SKYTokens, USDSTokens, and USDTTokens.
Material Events
8-K
Strategy Change
March 23, 2026
High Impact
- Complete and immediate shift from pharmaceutical business to stablecoin development, rebranding as "Stablecoin Development Corporation" (SDEV).
- Secured a significant $134 million investment from key crypto players including R01 Fund LP, Framework Ventures, Sky Frontier Foundation, and Tether Investments.
8-K
Financial Distress
February 20, 2026
High Impact
- NovaBay Pharmaceuticals executed a 1-for-5 reverse stock split to bolster its stock price and market position.
- The split aims to regain compliance with NYSE American's minimum bid price requirement and prevent delisting.
8-K
Strategy Change
February 12, 2026
High Impact
- Aims to meet NYSE American's $1.00 minimum bid price to avoid delisting.
- Designed to attract broader institutional investment by increasing per-share price.
8-K
Financial Distress
January 28, 2026
High Impact
- NovaBay's independent auditor, WithumSmith+Brown, PC, has stepped down, confirming the company's dissolution path.
- The auditor's decision was not due to disagreements but directly stems from NovaBay's stockholder-approved plan of dissolution.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.